Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted.
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application. | March 30, 2023
Net revenue for the first half of 2022 increased 45.5% period-over-period to $42.8 million Positive results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell. | August 11, 2022
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights - read this article along with other careers information, tips and advice on BioSpace
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc.May 16, 2021 GMT
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year-end 2021
Ended first quarter 2021 with $291.5 million in consolidated cash, cash equivalents and restricted cash
NEW YORK, May 16, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced financial results and recent corporate highlights for the first quarter ended March 31,